Logo
About usInnovation CMChallengesEuropa2iEntrepreneurshipR&D&I SearchAgentsEventsReports
en
Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein UCP2CM Patents

Índice de la ficha

Updated at
24/07/2026
Numero publicacion
US.2002165280.A1
Fecha publicacion
07/11/2002
Numero solicitud
US20020041090
Fecha presentacion
07/01/2002

En detalle

Resumen

The invention relates to the use of a compound of the retinoid type particularly retinoid acid for the preparation of a medicament capable of modulating in vivo the decoupling activity of decoupling proteins. These compounds can be used conveniently for the treatment of diseases associated to an increase or reduction of the activity of decoupling proteins. According to a preferred embodiment, the retinoid acid will be used for the treatment of disease associate to a reduction of the decoupling activity of the protein UCP2 such as for example obesity.

Etiquetas

Inventores
Bouillaud FredericRicquier DanielRial Zueco Eduardo
Solicitantes
Bouillaud FredericRicquier DanielRial Zueco Eduardo
Clasificacion ipc
A61K 31/ 203 A I
Clasificacion cpc
514/559
Logo

Innovation CM
Challenges
Europa2i
Entrepreneurship
R&D&I Search
Agents
Events
Reports
About us
Contact
Give us your opinion
Cookies
Legal notice
Privacy

© Copyright Espacio Madrileño de Investigación e Innovación 2026